Fate Therapeutics, Inc. announced that in connection with the company's restructuring plan and reduction to its workforce, the employment of Mark Plavsic, Ph.D., D.V.M., the Company's Chief Technical Officer, is expected to terminate effective as of March 6, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.17 USD | +0.32% | -3.35% | -15.24% |
06-26 | Intellia Therapeutics Names Edward Dulac CFO | MT |
06-26 | Intellia Therapeutics, Inc. Announces Chief Financial Officer Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.24% | 360M | |
+16.61% | 121B | |
+17.75% | 110B | |
+17.23% | 25.98B | |
-24.11% | 19.27B | |
-18.56% | 15.99B | |
-18.47% | 15.66B | |
-47.75% | 14.5B | |
+57.35% | 14.47B | |
+5.62% | 13.91B |
- Stock Market
- Equities
- FATE Stock
- News Fate Therapeutics, Inc.
- Fate Therapeutics, Inc. Expects to Terminate Mark Plavsic as Chief Technical Officer, Effective as of March 6, 2023